Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
NCT06732245 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224
Last updated 2026-03-27
Summary
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
Conditions
- Obesity and Overweight
Interventions
- DRUG
-
NA-931
NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (Zepbound) placebo
- DRUG
-
Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound NA-931 Placebo (oral, daily)
- DRUG
-
Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist • Other Names: * Mounjaro * Zepbound NA-931 Placebo (oral, daily)
- DRUG
-
NA-931
NA-931, an oral, daily • A quadruple receptor agonist
- DRUG
-
NA-931
NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
- DRUG
-
NA-931
NA-931 (oral daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
- DRUG
-
NA-931 150 mg + no Tirzepatide
NA-931 150 mg + no Tirzepatide
- DRUG
-
NA-931
NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
- DRUG
-
NA-931
NA-931 (oral, daily), a quadruple receptor agonist Tirzepatide (s.c. weekly) * Glucagon-like peptide-1 (GLP-1) receptor agonist * Other Names: * Mounjaro * Zepbound
Sponsors & Collaborators
-
Bioneurals Ltd
collaborator UNKNOWN -
Biomed Industries, Inc.
lead INDUSTRY
Principal Investigators
-
Lloyd Tran, PhD · Biomed Industries, Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 19 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-08-15
- Primary Completion
- 2027-08-15
- Completion
- 2027-12-15
- FDA Drug
- Yes
Countries
- United States
- Australia
- New Zealand
Study Locations
More Related Trials
-
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
NCT06515418 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06595238 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
NCT05822544 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016 ·Status: COMPLETED ·Phase: PHASE3
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
NCT05912621 ·Status: RECRUITING ·Phase: PHASE2
-
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
NCT07036601 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
NCT04660643 ·Status: COMPLETED ·Phase: PHASE3
-
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
NCT06862791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
NCT06180616 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tirzepatide in Overweight and Very Overweight Participants
NCT04311411 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
NCT04844918 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
NCT05616013 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
NCT06847399 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of LY3841136 in Overweight and Obese Participants
NCT06345066 ·Status: COMPLETED ·Phase: PHASE1